The structural profiles are close, with Regeneron Pharmaceuticals carrying a narrow edge on stability. Vertex Pharmaceuticals still has the edge on stability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
Stability points more clearly toward Vertex Pharmaceuticals Incorporated, even if the broader score still leans toward Regeneron Pharmaceuticals, Inc..
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. REGN and VRTX share the same industry classification.
For a similarity-based comparison, see how Regeneron Pharmaceuticals and Vertex Pharmaceuticals each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in stability.
Left means cheaper relative valuation. Higher means stronger structure.
The structural gap is limited here, but current pricing still leans against Vertex Pharmaceuticals Incorporated.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where REGN and VRTX each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The clearest distance comes from a steadier profile over time.
Stability is the one area where Vertex Pharmaceuticals Incorporated still pushes back materially — it is the steadier name on this dimension, which keeps the result from reading as one-way.
Stability is the clearest driver of the lead, with valuation adding further support — though stability still provides a real counterweight.
Break down the REGN vs VRTX comparison across all dimensions with the full interactive tool.
Explore how REGN and VRTX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.